arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

BioXcel Therapeutics, Inc.

BTAI

$0.92 ▲ +0.09 (+10.84%) at close

10 Visible periods

26 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Excellent

Bullish

auto_awesome

Analytical Summary

BioXcel Therapeutics, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $11.2M

Dividend Yield —

Revenue Growth -71.7% ↘

Op. Margin —

ROIC -282.1% ↗

FCF / Share $-4.72 ↗

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity -1.15

info Valuation on last close. End-of-day price, Aug 7, 2026.

10-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$642.00K

↓ -71.7% —

Net Income Profit after all expenses

$-69.90M

↓ -17.3% —

FCF / Share Free cash flow per share

$-4.72

↑ +83.4% —

Long-Term Debt Long-term obligations

$109.59M

↑ +6.9% —

trending_up

Bullish Indicators

Debt to EquityDebt to Equity is in the top quartile (lower is better)
Return on Common Equity (%)Return on Common Equity (%) is in the top quartile

warning

Bearish Risks

No bearish risks detected.

Health Breakdown

Returns

Financial Health ↑

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Mar 29, 2017 10-K ↗
Revenue Growth YoY (%)	-71.7% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-996%)	64.2% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+703%)	268.0% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+3250%)	—	—	—	—	—	—	—
EPS Growth YoY (%)	75.6% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	76.1% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-3.8% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	-46.2% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	-6.9% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—
Net Income Growth YoY (%)	-17.3% Weak ↓ Weak Declining Year-over-year change in net income	66.7% Excellent ↑ Excellent Improving Year-over-year change in net income	-8.0% Weak ↑ Weak Improving Year-over-year change in net income	-55.0% Weak ↑ Weak Improving Year-over-year change in net income	-30.1% Weak ↑ Weak Improving Year-over-year change in net income	-149.2% Weak ↑ Weak Improving Year-over-year change in net income	-71.1% Weak Weak Year-over-year change in net income	-324.5% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	83.4% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	66.6% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-10.0% Weak ↑ Weak Improving Year-over-year change in free cash flow	-54.4% Weak Weak Year-over-year change in free cash flow	-1.9% Weak Weak Year-over-year change in free cash flow	—	—	—	—	—
Revenue CAGR 3Y (%)	19.6% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—	—	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Mar 29, 2017 10-K ↗
FCF / Net Income (x)	0.82x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.21x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	0.87x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.82x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.77x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.81x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.85x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.72x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.48x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Mar 29, 2017 10-K ↗
Return on Invested Capital (%)	-282.1% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-564.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-307.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-74.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-38.1% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-31.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-98.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-40.6% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	365.0% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-112.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-175.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-233.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-77.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-44.7% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-37.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-92.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-45.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	-334.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	73.2% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+388%)	64.0% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+327%)	—	-215.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1539%)	-48.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-422%)	-39.8% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-365%)	-122.6% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-917%)	-49.6% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-430%)	—	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Mar 29, 2017 10-K ↗
Debt to Equity (x)	-1.15x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-291%)	-1.10x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-284%)	-1.78x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-397%)	1.21x Caution Caution Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+102%)	—	—	—	—	—	—
Interest Coverage (x)	-3.29x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-4.59x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-14.39x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-19.44x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-2673.38x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-3048.04x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-1680.05x Weak Weak Operating income divided by interest expense Optimal: > 5x	-19962.00x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—
Net Debt (USD)	$81.18M	$72.65M	$35.38M	$-100.67M	$-232.97M	$-213.12M	$-32.43M	$-42.56M	$-887.00K	—
Debt / EBITDA (x)	-2.18x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-1.53x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.59x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.58x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—	—	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Mar 29, 2017 10-K ↗
Revenue per Share (USD)	$0.05	$0.89	$0.76	$0.21	—	—	—	—	—	—
Basic EPS, GAAP (USD)	$-5.73	$-23.51	$-98.33	$-94.72	$-64.80	$-60.64	—	—	—	—
Free Cash Flow per Share (USD)	$-4.72	$-28.41	$-85.13	$-77.38	$-50.11	$-49.19	—	—	—	—
Book Value per Share (USD)	$-4.28	$-30.01	$-30.20	$43.64	$126.76	$135.44	$23.79	$39.73	$-1.59	—
Tangible Book Value per Share (USD)	$-4.28	$-30.01	$-30.20	$43.64	$126.76	$135.44	$23.79	$39.73	$-1.59	—
Basic Weighted Avg Shares (shares)	12.21M	2.54M	1.82M	1.75M	1.65M	1.36M	—	—	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Mar 29, 2017 10-K ↗
Working Capital (USD)	$-9.24M	$15.16M	$44.88M	$169.97M	$220.15M	$205.22M	$25.64M	$38.51M	$-1.45M	—
LT Debt (USD)	$109.59M	$102.51M	$100.60M	$93.05M	—	—	—	—	—	—
Total Equity (USD)	$-95.46M	$-93.10M	$-56.51M	$76.78M	$221.67M	$206.70M	$26.89M	$38.89M	$-982.00K	$-314.00K

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Mar 29, 2017 10-K ↗
Sales/Revenue/Turnover (USD)	$642.00K	$2.27M	$1.38M	$375.00K	—	—	—	—	—	—
Depreciation Expense (USD)	$300.00K	$309.00K	$318.00K	$327.00K	$297.00K	$188.00K	$156.00K	$17.00K	$1.00K	—
Net Income, GAAP (USD)	$-69.90M	$-59.60M	$-179.05M	$-165.76M	$-106.93M	$-82.17M	$-32.97M	$-19.27M	$-4.54M	—
Operating Cash Flow (USD)	$-57.62M	$-72.03M	$-155.01M	$-135.34M	$-82.15M	$-66.35M	$-27.10M	$-13.51M	$-2.20M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 10 years · 38 quarters

BioXcel Therapeutics, Inc.

Analytical Summary

10-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare BTAI with peers